Overview

A Multi-Center Study to Evaluate the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Moderate-to-Severe Crohn's Disease

Status:
Completed

Trial end date:
2014-04-01

Target enrollment:

Participant gender:

Summary

The primary objective of the study is to estimate the treatment effect of PDA001 (evaluating 3 different PDA001 dosings) versus placebo in subjects with moderate-to-severe Crohn's Disease. The secondary objective of the study is to assess the safety and tolerability of PDA001 versus placebo in the above-mentioned patient population.

Phase:

Phase 2

Details

Lead Sponsor:

Celularity Incorporated

Collaborator:

Celgene Corporation